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Systematic analysis of mutation 
distribution in three dimensional 
protein structures identifies cancer 
driver genes
Akihiro Fujimoto1,2, Yukinori Okada3,4, Keith A. Boroevich5, Tatsuhiko Tsunoda5, 
Hiroaki Taniguchi1 & Hidewaki Nakagawa1
Protein tertiary structure determines molecular function, interaction, and stability of the protein, 
therefore distribution of mutation in the tertiary structure can facilitate the identification of new driver 
genes in cancer. To analyze mutation distribution in protein tertiary structures, we applied a novel three 
dimensional permutation test to the mutation positions. We analyzed somatic mutation datasets of 
21 types of cancers obtained from exome sequencing conducted by the TCGA project. Of the 3,622 
genes that had ≥3 mutations in the regions with tertiary structure data, 106 genes showed significant 
skew in mutation distribution. Known tumor suppressors and oncogenes were significantly enriched 
in these identified cancer gene sets. Physical distances between mutations in known oncogenes were 
significantly smaller than those of tumor suppressors. Twenty-three genes were detected in multiple 
cancers. Candidate genes with significant skew of the 3D mutation distribution included kinases 
(MAPK1, EPHA5, ERBB3, and ERBB4), an apoptosis related gene (APP), an RNA splicing factor (SF1), 
a miRNA processing factor (DICER1), an E3 ubiquitin ligase (CUL1) and transcription factors (KLF5 and 
EEF1B2). Our study suggests that systematic analysis of mutation distribution in the tertiary protein 
structure can help identify cancer driver genes.
Identification of driver genes from the mutation catalog is one of the most important issues in cancer genetics 
research. The identified driver genes can lead to development of new drugs and elucidate mechanisms of car-
cinogenesis1,2. One of the strongest signatures of cancer driver genes is the frequency of mutated samples and/or 
number of mutations. In recent studies, statistical comparison between the number of observed and expected 
mutations, i.e. gene burden test, has been performed and many driver genes have been discovered3,4. Although 
this framework has been used to successfully identify new driver genes and pathways, recent studies reveal that 
most cancers are very heterogeneous, and many low-frequency driver genes exist in the long-tailed mutated gene 
lists3,4. To discover low-frequency driver genes from huge lists of mutations, application of a new algorithms that 
focuses on new aspects of driver genes is required.
Driver genes are generally classified into oncogenes and tumor suppressor genes (TSGs). Mutations in onco-
genes render the gene constitutively active (gain of function) or confer a different function (change of function)2. 
On the other hand, mutations in TSGs reduce activity of the gene2. Since the amino acid residues that can activate 
protein function tend to be limited, mutations in oncogenes are likely to be tightly clustered to a few functionally 
important codons2. In the TSGs, missense mutations would be distributed in functionally important domains, 
such as the DNA binding domain in the TP53 gene5. This expectation predicts that mutations in driver genes are 
not randomly distributed, and analysis of mutation position in a gene can identify driver genes6–8.
In this study, we examined the skew of mutation distributions in the tertiary structures of the proteins. Our 
analysis revealed a different pattern of mutation distribution between oncogenes and TSGs, and identified driver 
1Laboratory for Genome Sequencing Analysis, RIKEN Center for Integrative Medical Sciences, Japan. 2Department of 
Drug Discovery Medicine, Graduate School of Medicine, Kyoto University, Japan. 3Laboratory for Statistical Analysis, 
RIKEN Center for Integrative Medical Sciences, Japan. 4Department of Human Genetics and Disease Diversity, 
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan. 5Laboratory for 
Medical Science Mathematics, RIKEN Center for Integrative Medical Sciences, Japan.  Correspondence and requests 
for materials should be addressed to A.F. (email: fujimoto@ddm.med.kyoto-u.ac.jp)
Received: 26 June 2015
Accepted: 03 May 2016
Published: 26 May 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:26483 | DOI: 10.1038/srep26483
genes and pathways. We consider that our method can complement traditional gene burden tests and contribute 
to a better interpretation of mutations in cancer genomes.
Results
Analysis method. In the present study, we developed a novel method to analyze mutation position in the 
tertiary (3 dimensional [3D]) structure of proteins. Since biochemical activities of proteins depend on their 
structure in vivo, it is reasonable to analyze mutation positions in the context of their 3D structure. To evaluate 
3 dimensional accumulation of mutations, we applied a permutation test (3D permutation test) (Fig. 1a and 
Supplementary Fig. 1). Protein 3D structures were downloaded from the Protein Data Bank (PDB), and the 
amino acid sequence of the protein structure was aligned to that of the reference genome using MAFFT9. Based 
on this alignment, mutations in the reference genome were mapped onto the 3D structure. For each gene with n 
mutations in the sequence covered by the 3D structure, the average pairwise Euclidean distance between the n 
mutations (observed average distance) was calculated.
To obtain the null distribution, n positions were randomly selected from the amino acid residues, and the 
average distance (simulated average distance) was calculated. This step was repeated 104~106 times to generate 
the null distribution of the simulated average distances. The significance of the observed distance was obtained 
from the null distribution (Fig. 1a, and Supplementary Fig. 1). Thus, the skew of mutation position was evaluated 
by the p-value. In addition to the 3D permutation test, we performed a simple permutation test for the observed 
average distance on the protein primary structure (1D permutation test).
Analysis of cancer somatic mutation data. We applied this method to exome sequence data from 7,215 
samples of 21 types of cancer released from the TCGA project (Supplementary Table 1)10–23. To remove possible 
germline SNVs, we examined two independent filters: Filter 1, removal of somatic mutation candidates that were 
present in the 1000genome common SNVs set, and Filter 2, removal of somatic mutation candidates were found 
in dbSNP with a validation status of “YES”. Filter 2 was more conservative but removed known cancer hotspots, 
therefore we adopted the result from filter 1 (Results from the filter 2 and comparison of the two filters can be 
found in Supplementary Tables 2 and 3 and the Supplementary information).
Using the filtered SNV set, we analyzed 3,622 genes with ≥ 3 missense mutations in the 3D structure using 
the 3D permutation test. AML did not have a sufficient number of somatic mutations, and no genes passed the 
Figure 1. Explanation of the 3D permutation test and significant genes. (a) 3D permutation test procedure. 
Average distance between mutations in the 3D structure is calculated. Significance was tested by a permutation 
test. (b) Significant genes in multiple cancers. Twenty-three genes were significant in multiple cancers. 
Annotation was based on Vogelstein et al.24. Two genes (CHEK2 and NR1H2) were identified in multiple 
cancers due to single hotspot in each gene. However, mutant alleles of these two hotspots were found in the 
dbSNP database (rs146546850 of CHEK2 and rs55817866 of NR1H2) and population allele frequencies were not 
low (0.7% for rs146546850 and 9.7% for rs55817866), therefore we removed these genes from this table.
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analysis criteria. Analysis with different minimum missense mutation cutoffs (≥ 4, 5, and 6) is provided in the 
Supplementary information. Quantile-quantile (Q-Q) plots of the permutation test did not show a systematic 
inflation of test statistics (Supplementary Fig. 2). After adjustment for multiple testing on the number of the ana-
lyzed genes, 188 genes (106 unique genes) had mutations in the > 3% of the samples with a false discovery rate 
(FDR) q-value ≤ 0.1 (Supplementary Table 2). Of the 21 evaluated cancer types, significant genes were identified 
in 20 cancer types. Of the 106 significant genes, 31 were significant across multiple cancers (Fig. 1b). To examine 
the reliability of the result, we examined whether known cancer genes were identified by the 3D permutation 
method. We adopted the annotation of tumor suppressor genes (TSGs) or oncogenes as defined by Vogelstein 
et al.24, and CSOMIC cancer gene census. The set of significant genes that were mutated in more than 3% of the 
samples were enriched for tumor suppressor genes (TSGs), oncogenes and COSMIC cancer genes (TSG; Fisher’s 
exact test p-value = 7.1 × 10−10, and odds ratio = 11.8, oncogene; p-value = 7.4 × 10−18, and odds ratio = 29.5, and 
CSOMIC cancer gene census gene; p-value = 5.9 × 10−19, and odds ratio = 9.0) (Fig. 2a–c), suggesting that our 
analysis can successfully identify driver genes.
We then analyzed frequency of mutated samples and observed average distance between mutations among 
significant oncogenes, TSGs, other significant genes and non-significant genes. Known TSGs were found 
to be mutated in a significantly larger number of samples than oncogenes (Fig. 2d). Known TSGs and onco-
genes were mutated in a significantly larger number of samples than the other genes (Fig. 2d). Since most of 
the TSGs and oncogenes were previously detected by frequency of mutated samples, it is reasonable that their 
frequencies are higher than the other genes. When conditioned on the length of coding sequences (CDS) of the 
respective genes, the adjusted average distances of the oncogenes were significantly lower than those of the TSGs 
(p-value = 7.2 × 10−6), indicating that the mutations in the oncogenes were more tightly clustered than those of 
the TSGs (Fig. 2e). The adjusted average distances of the other significant genes were significantly smaller than 
those of the TSGs (p-value = 2.8 × 10−8), but not more than those of the oncogenes. These results suggest that the 
other significant gene set likely includes potential oncogenes, which were difficult to identify using conventional 
frequency based methods.
Figure 2. Analysis of candidate driver genes. (a) Proportion of oncogenes. Oncogenes were enriched in the 
significant gene set (Fisher’s exact test; p-value = 7.4 × 10−18; odds ratio = 29.5). Sig gene - significant gene. NS 
gene - not significant gene. (b) Proportion of TSGs. TSGs were enriched in the significant gene set (Fisher’s 
exact test; p-value = 7.1 × 10−10; odds ratio = 11.8). (c) Proportion of genes in COSMIC cancer gene census. 
COSMIC cancer genes were enriched in the significant gene set (Fisher’s exact test; p-value = 5.9 × 10−19; odds 
ratio = 9.0). (d) Frequency of mutated samples for significant oncogenes, significant TSGs, the other significant 
genes and non-significant genes. Frequency of mutated samples of TSGs was significantly higher than that of 
oncogenes, the other significant genes and not significant genes. P-values were obtained by Wilcoxon’s rank 
sum test. Unadjusted p-values were shown. (e) Adjusted average distance between mutations in significant 
oncogenes, significant TSGs, the other significant genes and not significant genes. Average distance between 
mutations was adjusted by length of the coding region. Adjusted average distance of TSGs was significantly 
larger than that of oncogenes, and the other significant genes. Adjusted average distance of oncogenes, the 
other significant genes was significantly smaller than that of not significant genes. P-values were obtained by 
Wilcoxon’s rank sum test. Unadjusted p-values were shown.
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Comparison with other methods. We compared our method with the gene burden test and test for muta-
tion clustering. We applied the 3D permutation method to the mutation lists of BRCA, KIRC, LUSC and UCEC, 
which were analyzed by Lawrence et al.22, and compared the results for the testable genes by the 3D permutation 
method (the number of mutations in the 3D structure ≥ 3) (Supplementary Table 4, and Supplementary Fig. 3). 
First, we compared our result with that from MutSigCV, which is a gene burden test (Supplementary Fig. 3a). In 
the four cancer types, 16 genes were significant by both methods. Nineteen genes were found only by MutSigCV, 
likely due to the wide distribution of mutations in these genes. Fifty-nine genes were uniquely identified by our 
method. Second, we compared the 3D permutation method with results for LUSC and UCEC by MutSigCL22 
and OncodriveCLUST6, which are the methods to detect mutation clusters in the primary structure. In the four 
cancer types, sixty-eight genes were significant by only one method, and 19 and 9 genes were detected by two 
and three methods, respectively (Supplementary Fig. 3b). Thirty-five genes were identified as significant only by 
the 3D permutation method, which included the FGFR3, HRAS, and KEAP1 genes. Third, we compared the 3D 
permutation method with combined MutSig result, which were generated by merging p-values of three methods22 
(Supplementary Fig. 3c). In the four cancer types, 27 genes were significant by the both methods. Twenty-two 
genes were found only by MutSig. Fifty-one genes were uniquely identified by our method, which included the 
FGFR2, HRAS, NFE2L2 and DICER1 genes These results suggest that the 3D permutation method can compli-
ment the gene burden test and the previous methods to detect mutation clusters, and identify new candidates, 
although analysis is restricted to genes with 3D structures available.
Genes with skew in mutation distribution. The genes, TP53, PIK3CA, CTNNB1, KRAS, PTEN, HRAS, 
BRAF, CDKN2A, PIK3R1, NFE2L2, SPOP, and IDH1 showed a significant skew in the observed mutation distri-
bution in 3 or more different types of cancers. Most of them are known TSGs or oncogenes, suggesting they have 
universal roles in carcinogenesis. While the mutation distribution for most of genes showed similar patterns, 
CDKN2A gene in the HNSC samples had an additional hotspot (Supplementary Fig. 4). Additionally, we obtained 
important observations of BRAF. In LUAD, the distribution of mutation in BRAF was significantly skewed even 
after the removal of the known hotspot (codon 600) (Fig. 3a), suggesting functional effects of the non-hotspot 
mutations.
A significant skew was observed for eighteen genes in exactly 2 different types of cancers and 6 of them (NRAS, 
PPP2R1A, EGFR, FGFR3, ERBB2 and SMAD4) are classified as either a TSG or an oncogene. Additionally, RAC1 
and KEAP1 are known to be important driver genes25,26 (Fig. 3b). KMT2C, also called MLL3, encodes a chro-
matin regulator27. DHX9 and PARG had the same mutational hotspot across cancer groups (Supplementary 
Table 2). PARG, a poly (ADP-ribose) glycohydrolase, is known to remove ADP-ribosylation of some DNA repair 
proteins recruited to DNA damage sites and can influence the activity of the DNA repair system along with 
PARP128. DHX9 encodes a DEAH-box DNA/RNA helicase that catalyzes the ATP-dependent unwinding of 
double-stranded RNA and DNA-RNA complexes29,30. DHX9 plays important roles in multiple cellular pathways, 
including protein translation, RNA splicing, maintenance of genomic stability and apoptosis29,30. Since DHX9 and 
PARG were mutated in less than 5% of the samples, they would have been difficult to identify through conven-
tional frequency based methods. In addition, known cancer driver genes that are often mutated at low frequency 
among samples, such as BRAF in LUAD, NFE2L2 in HNSC, CDKN2A in LUAD and PIK3CA in GBM, were iden-
tified by the 3D permutation test. This result strongly suggests the important role of these genes in certain cancers.
Seventy-five genes were identified in only one type of cancer. Of these, 58 genes were neither classified as 
an oncogene nor a TSG, and 54 were not in the COSMIC cancer gene census. The seventy-five genes included 
TSGs (VHL, BAP1, HNF1A, PBRM1, and, RB1), oncogenes (AKT1, FGFR2, GNAS, MAP2K1, and MET), kinases 
(MAPK1, EPHA5, ERBB3, and ERBB4), an apoptosis related gene (APP), an RNA splicing factor (SF1), a miRNA 
processing factor (DICER1), an E3 ubiquitin ligase (CUL1) and transcription factors (KLF5 and EEF1B2) 
(Supplementary Table 2) (DICER1 and FAS are shown as examples in Fig. 3c,d).
Pathway analysis. To identify pathways related to the putative driver genes, we analyzed pathway enrich-
ment in the reactome database, and identified 326 pathways with an FDR < 0.1 (Supplementary Table 5). Since 
most of these pathways were already known critical pathways, we excluded genes annotated as oncogenes and 
TSGs, and carried out the same analysis for the remaining 71 genes. One hundred seventy-two pathways were 
significantly enriched (Supplementary Table 6), including pathways related to “axon guidance” and “semaphorin”. 
Genes related to the axon guidance pathway were identified in pancreatic and liver cancers31,32. Semaphorin is 
involved in tumor growth, invasiveness and metastasis, and our analysis provides supportive evidence of the 
importance of the semaphorin pathway in carcingenesis33.
Comparison between the 3D and 1D permutation tests. We then compared the results between the 
3D and 1D permutation tests (Note that 1D permutation was done for entire coding regions, but 3D permutation 
analysis was limited to coding region in the 3D protein structure) (Supplementary Fig. 5). For the 1D permutation 
tests, 141 genes (80 unique genes) had a significantly skewed observed average distance between mutations, 44 of 
which were commonly identified by both the 3D and 1D permutation tests (Supplementary Fig. 6). The number 
of significant genes found in the 3D analysis was larger than that of 1D analysis. We compared the proportion 
of known TSGs, oncogenes and COSMIC cancer genes among the genes identified by the both methods, only 
the 1D test, and only the 3D test. As expected, commonly identified genes had the highest proportion of these 
cancer-related genes (Supplementary Fig. 6). Genes identified by only the 3D test had a larger proportion of 
oncogenes, TSGs and COSMIC cancer genes than these of the 1D test (COSMIC cancer genes; P-value = 0.028, 
oncogenes and TSGs were not significantly different) (Supplementary Fig. 6).
Focusing on each gene, driver genes, such as ERBB2, KIT, HNF1A and GNAS, were not identified in the 1D 
analysis (Supplementary Fig. 7a–d). In addition to the known driver genes, our 3D analysis identified CUL1 
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Figure 3. Examples of the significant genes identified by the 3D permutation. Primary structure, 3D 
structure, and mutations are shown. Amino acid sequence and 3D structure are shown. Recurrently mutated 
codons are indicated by the square in the amino acid sequence, and the position of the codons are shown in 
the 3D structures. Figures of the 3D structure were generated by VMD software. (a) BRAF. q-value of 3D 
permutation (q-value3D) < 10−6. q-value of 1D permutation (q-value1D) < 10−6. Codon 600 (hotsopt) is shown 
in blue in the 3D structure. (b) RAC1. NHSC: q-value3D < 10−6. q-value1D  =  n.s. (not significant). SKCM: 
q-value3D < 10−6. q-value1D = 0.0067. Mutations in NHSC and SKCM are shown in blue and orange, respectively. 
The common mutation is shown in red. (c) DICER1. UCEC: q-value3D = 0.0044. q-value1D = n.s. Sequence in 
the structure correspond to RNase III domain in DICER1. (d) FAS. CESC; q-value3D = 0.025. q-value1D = n.s. 
Change at codon 240 causes loss of interaction with FADD38. Two other mutations are close to the codon 
240 in the 3D structure, suggesting that these positions are functionally important as well. (e) KRAS. BLCA: 
q-value3D = 0.0020. q-value1D = n.s. Codon 12 (hotsopt) is shown in blue in the 3D structure.
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as a candidate driver gene (Supplementary Fig. 7e). CUL1, a known cell cycle regulator, is a member of the 
Skp1-Cul1-F-box ubiquitin ligase complex, which functions as both a tumor suppressor and oncogene through 
degradation of its target proteins34,35. Accordingly, 3D permutation analysis should be favored over 1D analysis as 
it confers several advantages including the efficient identification of oncogenes and TSGs.
We manually reviewed the genes identified only by the 3D permutation test, and found interesting examples. 
Several recurrently mutated codons, whose frequency was not enough high to be identified by the 1D analysis, were 
clustered in the 3D structure in RAC1 of HNSC, DICER1 of UCEC and KIT of SKCM (Fig. 3b,c and Supplementary 
Fig. 7b). One recurrently mutated codon and positionally close mutation(s) were found in KRAS of BLCA, ERBB2 
of CESC and GNAS of SKCM (Recurrently mutated codons were codon 12 of KRAS, codon 279 of ERBB2 and 
codon 844 of GNAS. Codon 12 of KRAS, and codon 844 of GNAS are known as the hotspots of the genes) (Fig. 3e 
and Supplementary Fig. 7a,e). In KRAS, one mutation (codon 61) was close to the known hotspot (codon 12) 
in the 3D structure (Fig. 3e). Mutations at codon 61 were also observed in other cancers (COAD, READ, STAD 
and UCEC), and the mutation was known to have a functional effect36. These examples show that the analysis 
of mutation distribution in the 3D structure merge mutated codons, which would not be detected as a mutation 
cluster by 1D analysis, and thus increases detection power for driver gene identification.
Discussion
The 3D permutation method successfully identified many known oncogenes, TSGs and promising candidates of 
cancer driver genes. Interestingly, our analysis identified a number of TSGs, in addition to the oncogenes, sug-
gesting that skew of mutation distribution is a general feature of TSGs. Although the mutations in the oncogenes 
are tightly clustered and sensitivity of the 3D permutation method for oncogenes should be higher than that of 
TSGs, analysis of the mutation distribution can identify TSGs. The functional analysis of close mutations in the 
TSGs could help define new motifs and critical regions. Previously, Ryslik et al. proposed methods to and success-
fully identified mutation clusters in the 3D structure7,8. Their methods focused on small mutation clusters, which 
can be candidates for drug development, and majority of the identified genes were oncogenes. In this study, we 
examined the skew of mutation positions in the proteins, and identified both oncogenes and TSGs. We consider 
that the 3D permutation method we implement is more straight-forward and, as evident above, can identify TSGs.
In addition to identifying genes that showed a significant skew in mutation distributions, we were also able 
to identify skews in domains known to be important. For example, the RNase III domain of DICER1, which is a 
known mutational hotspot domain37, showed significant skew of mutation distribution (Fig. 3b). This suggests 
that mutation distributions are not uniform within a domain, and such analyses could contribute to the identifi-
cation of functionally important amino acid positions within the domain.
We note that our method has several limitations to be assessed in future. First, this analysis is limited to muta-
tions in genes with available 3D protein structures, and therefore genes/proteins without 3D information cannot 
be analyzed. It is also difficult to obtain 3D structures for the entire protein, for example, structures of trans-
membrane regions are difficult to examine. In our analysis, only 3,622 genes had 3 or more mutations in regions 
for which protein structures were available. Second, protein structures in PDB may not always accurately reflect 
protein structure in vivo. Third, errors in mutation call from sequencing analysis can affect these results, espe-
cially, if common germline SNVs are not called in multiple normal samples and identified in their matched cancer 
samples. The germline SNVs would be identified as clustered mutations. Since such types of errors should be rare, 
we excluded mutations found in the 1000 genomes common set and focused on genes that are mutated in ≥ 3% of 
the samples. However, a small number of false positives caused by germline SNVs may still be included in our list. 
Fourth, our method implicitly assumes that the mutation rate in a gene is uniform in the protein structure. This 
assumption should be appropriate for most genes, but may fail for some larger genes. For example, TTN, one of 
the largest genes, was significant in two cancers, and this may result from non-uniform mutation rate across the 
TTN gene region. Although analysis of the skew of distribution of synonymous mutations may make it possible to 
test the mutation rate variation in a gene, the number of the synonymous mutations in the downloaded data is too 
small to analyze. In the future, we will be able to obtain a larger number of mutations, and test the mutation rate 
variation with synonymous mutations. The contamination of germline SNVs and non-uniform mutation rates in 
a gene may explain the slight inflation seen in the Q-Q plots (Supplementary Fig. 2).
Together, our analysis systematically identified skewed mutation distributions in the 3D protein structure of 
106 genes, which include many strong candidate driver genes with various biological functions. Further func-
tional analysis of these candidates and the mutations should elucidate the mechanism of carcinogenesis and their 
status as driver genes. Since an accumulation of mutations in a protein can also indicate a good drug target, our 
methodology can be applied to future drug development, in addition to the identification of low frequency driver 
genes.
Methods
Data. Mutation data was downloaded from TCGA web site. MAF files with a data status of “No restrictions; 
all data available without limitations” were downloaded on December 19th, 2015 (Supplementary Table 1). 
Redundant SNVs in same sample were removed. To remove possible germline variations, we performed two 
kinds of SNVs filters: Filter 1, removal of somatic mutation candidates that were found in the 1000genome com-
mon SNV set, and Filter 2, removal of somatic mutation candidates that were found in dbSNP with a validation 
status of “YES”. The number of germline SNVs in dbSNP is much larger than these in 1000geome and filter 2 
is the more conservative filter and, remove important hotspots in cancer as suggested in Jung et al.39. Indeed, 
known hotspots in BRAS, KRAS and GNAS were removed by filter 2. Therefore we discussed the results of filter 1 
in the paper. All files in a cancer type were merged and annotated with gene information of GENCODE v19 
(http://www.gencodegenes.org). Remaining SNVs that resulted in missense mutations were selected for 
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analysis. Commands to visualize mutation position in the 3D structure in Chimera software were provided in the 
Supplementary Table 2.
Protein 3D structures were downloaded from PDB on August 7th, 2014.
Annotation of oncogenes and TSGs was based on Table S2A in Vogelstein et al.10. Cancer gene census was 
obtained from COSMIC.
Comparison with other methods. We compared out methods with different methods; MutSigCV, 
MutSigCL, combined result of MutSig and OncodriveCLUST. MutSigCV is a gene burden test, and MutSigCL and 
OncodriveCLUST are methods to identify mutation clusters in the primary structure. The P-values of MutSigCV 
and MutSigCL were obtained from Lawrence et al.22. In the paper, 21 cancers were analyzed, and we selected 
four cancer types (BRCA, KIRC, LUSC, and UCEC), because mutation lists used in the study on the GRCh37 
were available from TCGA database. P-values for MutSigCV, MutSigCL were obtained from Lawrence et al.3, 
and correction for the multiple testing was by Benjamini and Hochberg’s method40 with n = 18,388 according to 
Lawrence et al.3. We also compared the result of MutSigCL and OncodriveCLUST for LUSC and UCEC, whose 
results were available from previous publications6,22.
Statistical methods. To quantify the skew of the mutation distribution, we applied a permutation test 
(Supplementary Fig. 1). Not all protein structures are human in origin, and most are not of the full length coding 
region. Because of this, we aligned the amino acid sequence of the protein structure to the translated reference 
genome using MAFFT9. Amino acid sequence aligned to human sequence with ratio of gaps to length of the 
alignment < 0.5 and ratio of aligned sequence length to total sequence length ≥ 0.5 were used for the analysis. 
Using the alignment, we converted the positions of the mutations to those in the 3D structures.
Using the positions in the 3D proteins, we tested the skew in mutation position distribution. We calculated 
the pairwise Euclidian distances between mutations in the 3D protein structure, and averaged the distances 
(observed average distance). Given a gene with n mutations in the 3D structure, average pairwise Euclidian dis-
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where (x, y, z) are location of amino acid residue in the 3D structure.
To test the significance of the observed average distance, we applied a permutation test. For gene with n 
mutations, n positions were randomly selected from the amino acid residues, and calculated average distances 
(simulated average distance) with the above formula. This step was repeated m times and the distribution of 
the simulated average distances was generated and used as the null distribution for the gene. (Fig. 1a, and 
Supplementary Fig. 1). We initially performed 10,000 permutations for each gene. To accurately estimate small 
p-values, genes with p-value ≤ 0.01 were reanalyzed using 1,000,000 permutations. If one gene had multiple 3D 
structures, the 3D structure with the lowest p-value was selected. Correction for multiple testing was done with 
the Benjamini and Hochberg’s method40.
We also analyzed the primary structure. We calculated the distance between mutations in the amino acid 




















where x is position of the mutation in the primary structure. The calculation, selection of a p-value and correction 
of the multiple testing were carried out as done for the 3D permutation.
Software. Program for the 3D permutation method is available (3D permutation; https://github.com/afuji-
moto/3Dpermutation.git).
URLs and software. 
PDB; http://www.rcsb.org/pdb/home/home.do
Source of the 3D structures; ftp://ftp.wwpdb.org/pub/pdb/data/structures/divided/pdb/
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